OnDemand 1st Joseph Markoff, PhD, MD Endowed Lecture: Reza Dana, MD, MSc, MPH

Guest Lecture:

New Ways of Doing Old Things: Translational Investigations in Management of Common Corneal and Ocular Surface Disorders
Reza Dana, MD, MSc, MPH
Harvard Ophthalmology
Vice Chair for Academic Programs
Director, Harvard-Vision Clinical Scientist Development Program
Co-director, Cornea Center of Excellence
Harvard Medical School
Member, PhD Program in Immunology, Harvard University
Mass Eye and Ear
Director, Cornea and Refractive Surgery Service
Senior Scientist (Schepens Eye Research Institute) 
Associate Chief for Academic Programs

Program Chair:
Leslie Hyman, PhD

1. Describe the most common approaches to treating corneal and ocular surface disorders.
2. Apply modern innovations to established treatments of corneal disease.

AMA PRA Statement
Wills Eye Hospital designates this Enduring Material for a maximum of 1.00 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Mitigation of Relevant Financial Relationships

In compliance with the Standards for Integrity and Independence in Accredited Continuing Education set by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of Wills Eye Hospital that the information presented at CME activities will be commercially unbiased and based upon clinical and scientific evidence. To help participants make judgments about the presence of commercial bias, Wills Eye Hospital provides information that all individuals in a position to control the content of a CME activity (including faculty, planners, reviewers or others) have disclosed about all financial relationships they have with ineligible companies. All relevant financial relationships have been mitigated.

Ineligible companies are companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if the educational content an individual can control is related to the business lines or products of the ineligible company. The CME activity staff at Wills Eye Hospital report no financial relationships with ineligible companies.

Member Information

Role in activity

Nature of Relationship(s) / Name of Ineligible Company(s)

Reza Dana, MD, MPH
Harvard Dept Ophthalmology/Mass Eye and Ear

Faculty

Consulting Fee-Amgen (Relationship has ended)|Private Corp Stock-Aramis Biosciences|Private Corp Stock-Claris Biotherapeutics

Leslie Hyman, PhD
Wills Eye Hospital/TJU

Peer Reviewer, Planner

Nothing to disclose

Natasha Kolomeyer, MD
Wills Eye Hospital

Planner

Consulting Fee-Allergan (Relationship has ended)|Consulting Fee-Thea (Relationship has ended)|Grant or research support-Guardion Health Services Inc (Relationship has ended)|Grant or research support-Equinox|Grant or research support-Nicox|Grant or research support-Olleyes|Grant or research support-Santen Pharmaceuticals|Grant or research support-Glaukos Corporation|Grant or research support-Diopsys|Grant or research support-Aerie Pharmaceuticals

Sarah Pyfrom, PhD
Wills Eye Hospital

Planner

Nothing to disclose

Zeba A. Syed, MD
Wills Eye Hospital

Planner

Speakers Bureau-Bio-Tissue|Advisor-Bio-Lattice|Consulting Fee-Bruder|Grant or research support-Dompé |Speakers Bureau-Tarsus|Consulting Fee-Glaukos Corporation|Consulting Fee-Recordati